Katalin Karikó
Katalin Karikó (, ; born 17 January 1955) is a Hungarian biochemist who specializes in RNA-mediated mechanisms. Her research has been the development of in vitro-transcribed mRNA for protein therapies. She co-founded and was CEO of RNARx, from 2006 to 2013. Since 2013, she has been a vice president and promoted to senior vice president in 2019 at BioNTech RNA Pharmaceuticals. She is also an adjunct professor at the University of Pennsylvania.

Karikó's work includes the scientific research of RNA-mediated immune activation, resulting in the co-discovery with American immunologist Drew Weissman of the nucleoside modifications that suppress the immunogenicity of RNA. This is seen as permitting the therapeutic use of mRNA. Together with Weissman, she holds U.S. patents for the application of non-immunogenic, nucleoside-modified RNA. This technology has been licensed by BioNTech and Moderna to develop their COVID-19 vaccines.
Q28
Hungarian
LOC
Q2919046
biochemist
Concept
Q11053
RNA
Concept
Q221681
in vitro
Concept
Q177900
transcribed
Concept
Q188928
mRNA
Concept
Q30256699
BioNTech
ORG
Q357813
adjunct professor
Concept
Q49117
University of Pennsylvania
ORG
Q88608402
Drew Weissman
UNK
Q103194381
nucleoside modifications
Concept
Q1660197
immunogenicity
Concept
Q11053
RNA
Concept
Q30256699
BioNTech
ORG
Q17081612
Moderna
ORG
Q87719492
COVID-19 vaccine
Concept
Q88608397
Katalin Karikó
PER
1955-01-17T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
17 January 1955
DATE
2006-01-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
2006
DATE
2013-01-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
2013
DATE
2013-01-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
2013
DATE
2019-01-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
2019
DATE
-19^^http://www.w3.org/2001/XMLSchema#decimal
-19
NUMBER
country of citizenship
occupation
date of birth
field of work
employer
employer
employer